Champions Oncology, Inc. — Form 10-Q Summary
Reporting period: Three months ended July 31, 2014 (first quarter of fiscal 2015). Unless stated otherwise, financial amounts are in U.S. dollars.
Business context
The company develops and sells oncology solutions using its TumorGraft platform. Personalized Oncology Solutions (POS) serves physicians and patients; Translational Oncology Solutions (TOS) serves pharmaceutical and biotechnology companies.
Financial performance and liquidity
| Metric | Three months ended July 31, 2014 | Prior-year comparable period |
|---|---|---|
| Revenue | $1.912 million | $3.020 million |
| Operating loss | $3.729 million | $0.766 million |
| Net loss | $3.548 million | $2.232 million |
| Net loss per share, basic and diluted | $0.05 | $0.03 |
| Cash used in operating activities | $2.788 million | $2.144 million |
- Revenue comprised POS of $341,000 and TOS of $1.571 million. Reported gross margins were negative 122% for POS and 38.6% for TOS.
- At July 31, 2014, cash and cash equivalents were $3.052 million, working capital was $1.1 million, and total liabilities were $5.239 million. Stockholders’ equity was $439,000.
- Cash declined $2.839 million during the quarter. Investing activities used $33,000; financing activities provided no cash.
- No debt is shown on the balance sheet. The company reported a $1.856 million warrant liability, measured using Level 3 inputs.
Changes versus prior-year quarter
- Revenue fell 36.7%: POS decreased 45.2% and TOS decreased 34.5%. Management attributed POS weakness to fewer completed drug panels, fewer tests per panel, and reduced non-core revenue; TOS declined on lower sales volume.
- Total costs and operating expenses increased 49.0% to $5.641 million. Research and development rose 254% to $1.423 million, reflecting increased investment in the tumor bank; sales and marketing rose 61.1% to $1.034 million as the TOS business development team expanded; general and administrative expense rose 36.5% to $1.462 million, partly due to compensation and stock compensation.
- Operating loss widened substantially. Other income improved by $1.649 million, mainly because warrant revaluation produced $155,000 of income versus $1.462 million of expense in the prior-year quarter. This revaluation did not affect cash.
- Stock-based compensation was $808,000, up from $552,000. The quarter-end share count outstanding was 66,885,741; options and warrants represented 26,658,954 potential common shares, excluded from diluted loss per share as anti-dilutive.
Outlook, risks and unusual items
- Management said available cash was expected to fund operations through at least December 31, 2014, but additional external capital would be needed to continue beyond that point. The filing warns that financing may not be available on acceptable terms or at all; absent financing, the company may have to reduce, delay, or eliminate activities.
- The company expects operating losses to continue until revenue increases sufficiently. No quantified revenue or earnings guidance is provided.
- Equity financing could dilute shareholders; debt financing could bring significant payment obligations and restrictive covenants. The company reported recent annual losses as well as a $3.548 million quarterly loss.
- The company terminated its exclusive option agreement concerning Irinophore C on June 26, 2014. It recognized $322,000 of quarterly revenue under its Teva agreement.
- Potential registration-default penalties of $50,000 to $130,000 for each 30-day period were not accrued because management did not consider payment probable. The filing reported no known legal proceedings.
- Management concluded disclosure controls were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the company obtained sufficient external financing after the stated cash runway through December 31, 2014, and on what terms.
- Whether POS and TOS revenue, sales volume, and gross margins improved from the quarter’s depressed levels.
- How the increased tumor-bank and sales-team investment affected operating costs, cash burn, and future revenue.
- The potential dilution and accounting effects of outstanding options and warrants, including changes in the warrant liability and any registration-rights penalties.
- Whether the Teva agreement generated further milestones, royalties, or other revenue after the reported $322,000.